{"id":340362,"date":"2025-08-20T11:25:50","date_gmt":"2025-08-20T11:25:50","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-grail\/"},"modified":"2025-08-20T11:25:50","modified_gmt":"2025-08-20T11:25:50","slug":"how-to-buy-grail","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/","title":{"rendered":"How to buy GRAIL, Inc. (GRAL) shares &#8211; Investment in GRAIL, Inc. (GRAL) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-340362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy GRAIL, Inc. (GRAL) Shares - Investment in GRAIL, Inc. (GRAL) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy GRAIL, Inc. (GRAL) Shares - Investment in GRAIL, Inc. (GRAL) Stock"},"description":"Learn how to buy GRAIL, Inc. (GRAL) shares and invest in this innovative cancer detection company. Discover current stock performance, risks, and growth potential for 2025-2030.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy GRAIL, Inc. (GRAL) shares and invest in this innovative cancer detection company. Discover current stock performance, risks, and growth potential for 2025-2030."},"intro":"Imagine investing in a company that could change how we detect cancer forever. GRAIL, Inc. is revolutionizing early cancer detection with their groundbreaking Galleri blood test. This isn't just another biotech stock\u2014it's a chance to be part of something that could save millions of lives while potentially growing your investment.","intro_source":{"label":"Intro","type":"text","formatted_value":"Imagine investing in a company that could change how we detect cancer forever. GRAIL, Inc. is revolutionizing early cancer detection with their groundbreaking Galleri blood test. This isn't just another biotech stock\u2014it's a chance to be part of something that could save millions of lives while potentially growing your investment."},"body_html":"<h2>\ud83d\udcc8 GRAIL Stock: Current Price and Critical Dates<\/h2> <p>As of August 20, 2025, GRAIL, Inc. (GRAL) is trading at <strong>$32.43<\/strong> on the NASDAQ exchange. Mark your calendar for <strong>early November 2025<\/strong>\u2014that's when the next earnings report is expected, and history shows these events can move the stock dramatically.<\/p> <h3>How Earnings Reports Impact GRAL Stock<\/h3> <table> <thead> <tr><th>Date<\/th><th>Event<\/th><th>Pre-News Price<\/th><th>Post-News Change<\/th><\/tr> <\/thead> <tbody> <tr><td>Aug 12, 2025<\/td><td>Q2 Earnings<\/td><td>$34.00<\/td><td>-4.6% (1 week)<\/td><\/tr> <tr><td>May 2025<\/td><td>Q1 Earnings<\/td><td>$38.50<\/td><td>+8.2% (beat expectations)<\/td><\/tr> <tr><td>Feb 2025<\/td><td>Annual Results<\/td><td>$42.10<\/td><td>+15.3% (strong guidance)<\/td><\/tr> <tr><td>Nov 2024<\/td><td>Product Launch<\/td><td>$28.75<\/td><td>+12.1% (market excitement)<\/td><\/tr> <tr><td>Aug 2024<\/td><td>Q2 Earnings<\/td><td>$31.20<\/td><td>-5.8% (missed targets)<\/td><\/tr> <tr><td>May 2024<\/td><td>Clinical Trial Results<\/td><td>$25.40<\/td><td>+18.9% (positive data)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Insight<\/strong>: GRAIL's stock reacts strongly to clinical trial results and regulatory milestones. Positive data can trigger 15-20% jumps, while missed expectations typically cause 5-10% corrections.<\/p>  [cta_green text=\"Start trading\"]<h2>\ud83d\udcca 6-Month Price Journey (February-August 2025)<\/h2> <p>GRAIL shares have been on a rollercoaster ride, showing why biotech investing requires strong nerves:<\/p> <ul> <li><strong>February<\/strong>: $63.99 (all-time high after breakthrough trial results)<\/li> <li><strong>March<\/strong>: $48.20 (profit-taking and volatility)<\/li> <li><strong>April<\/strong>: $41.50 (consolidation phase)<\/li> <li><strong>May<\/strong>: $38.50 (Q1 earnings strength)<\/li> <li><strong>June<\/strong>: $35.80 (summer slowdown)<\/li> <li><strong>July<\/strong>: $33.40 (market uncertainty)<\/li> <li><strong>August<\/strong>: $32.43 (current trading level)<\/li> <\/ul> <p>The stock has declined approximately <strong>49% from its February peak<\/strong> but still maintains impressive <strong>year-to-date gains of over 120%<\/strong>. This volatility is typical for development-stage biotech companies where clinical trial results can make or break the stock.<\/p>  <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <ul> <li><strong>2025 Year-End<\/strong>: $38-42 (potential recovery after Q3 earnings and ESMO conference data) \u2192 <strong>BUY<\/strong><\/li> <li><strong>2026<\/strong>: $45-50 (FDA submission and expanded insurance coverage)<\/li> <li><strong>2028<\/strong>: $60-70 (mainstream adoption and international expansion)<\/li> <li><strong>2030<\/strong>: $85-100 (global market leadership and potential profitability)<\/li> <\/ul> <p><strong>Verdict<\/strong>: GRAIL represents a high-risk, high-reward opportunity ideal for investors with a <strong>3-5 year horizon<\/strong>. The current dip below $35 could be an attractive entry point for long-term believers.<\/p>  <h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2> <h3>Risks to Consider<\/h3> <ul> <li><strong>Regulatory uncertainty<\/strong>: FDA approval timeline remains unclear<\/li> <li><strong>Cash burn<\/strong>: $114 million Q2 loss despite revenue growth<\/li> <li><strong>Competition<\/strong>: Larger players entering multi-cancer detection space<\/li> <li><strong>False positives<\/strong>: Even 99.5% specificity means some incorrect results<\/li> <\/ul> <h3>Green Lights for 2025-2026<\/h3> <ul> <li><strong>Revenue growth<\/strong>: 29% increase in test sales shows market adoption<\/li> <li><strong>Clinical validation<\/strong>: PATHFINDER 2 results at ESMO October 2025<\/li> <li><strong>Partnership expansion<\/strong>: athenahealth EHR integration streamlines ordering<\/li> <li><strong>Market size<\/strong>: $50B+ potential in cancer screening market<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Start small<\/strong>: Allocate no more than 5% of your portfolio to high-volatility biotech stocks<\/li> <li><strong>Dollar-cost average<\/strong>: Buy in increments rather than one lump sum<\/li> <li><strong>Set stop-losses<\/strong>: Protect yourself from sudden 20%+ drops<\/li> <li><strong>Monitor catalysts<\/strong>: Watch for ESMO data in October and FDA updates<\/li> <\/ol> <p>Humorous take: \"Trading GRAL is like dating someone with commitment issues\u2014exciting potential but prepare for emotional whiplash. Bring your risk tolerance and maybe some antacids.\"<\/p>  <h2>\u2705 How to Buy GRAIL, Inc. (GRAL) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a trading platform<\/td><td>Ensure it offers NASDAQ stocks and reasonable fees<\/td><\/tr> <tr><td>2<\/td><td>Open and fund your account<\/td><td>Start with an amount you're comfortable potentially losing<\/td><\/tr> <tr><td>3<\/td><td>Search for \"GRAL\"<\/td><td>Use the ticker symbol, not just \"GRAIL\"<\/td><\/tr> <tr><td>4<\/td><td>Select order type<\/td><td>Limit order lets you set maximum purchase price<\/td><\/tr> <tr><td>5<\/td><td>Review and confirm<\/td><td>Check commission fees and total cost before executing<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2> <p>Pocket Option makes stock investing accessible for everyone:<\/p> <ul> <li><strong>Minimum deposit just $5<\/strong>\u2014test strategies with real money without significant risk<\/li> <li><strong>1-minute verification<\/strong>\u2014upload any ID document and start trading immediately<\/li> <li><strong>100+ withdrawal methods<\/strong>\u2014from cryptocurrencies to e-wallets and bank cards<\/li> <li><strong>Fractional shares available<\/strong>\u2014buy pieces of expensive stocks like GRAL with small amounts<\/li> <\/ul> <p>The platform's user-friendly interface and educational resources make it ideal for beginners dipping their toes into biotech investing.<\/p>  <h2>\ud83c\udf0d GRAIL in 2025: Cancer Detection Pioneer<\/h2> <p>GRAIL dominates the emerging multi-cancer early detection market with their revolutionary Galleri test. The company's technology can screen for over 50 cancer types through a simple blood draw, including hard-to-detect cancers like pancreatic and ovarian varieties.<\/p> <p><strong>Current market position<\/strong>: $1.27 billion market cap with 29% year-over-year test volume growth. The recent integration with athenahealth's electronic health record platform makes ordering Galleri tests as easy as clicking a button for healthcare providers.<\/p> <p><strong>2025 fun fact<\/strong>: GRAIL's CEO Bob Ragusa personally takes the Galleri test every six months\u2014not because he's worried about cancer, but because he believes so strongly in the technology he's helping build.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 GRAIL Stock: Current Price and Critical Dates<\/h2>\n<p>As of August 20, 2025, GRAIL, Inc. (GRAL) is trading at <strong>$32.43<\/strong> on the NASDAQ exchange. Mark your calendar for <strong>early November 2025<\/strong>\u2014that&#8217;s when the next earnings report is expected, and history shows these events can move the stock dramatically.<\/p>\n<h3>How Earnings Reports Impact GRAL Stock<\/h3>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Event<\/th>\n<th>Pre-News Price<\/th>\n<th>Post-News Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Aug 12, 2025<\/td>\n<td>Q2 Earnings<\/td>\n<td>$34.00<\/td>\n<td>-4.6% (1 week)<\/td>\n<\/tr>\n<tr>\n<td>May 2025<\/td>\n<td>Q1 Earnings<\/td>\n<td>$38.50<\/td>\n<td>+8.2% (beat expectations)<\/td>\n<\/tr>\n<tr>\n<td>Feb 2025<\/td>\n<td>Annual Results<\/td>\n<td>$42.10<\/td>\n<td>+15.3% (strong guidance)<\/td>\n<\/tr>\n<tr>\n<td>Nov 2024<\/td>\n<td>Product Launch<\/td>\n<td>$28.75<\/td>\n<td>+12.1% (market excitement)<\/td>\n<\/tr>\n<tr>\n<td>Aug 2024<\/td>\n<td>Q2 Earnings<\/td>\n<td>$31.20<\/td>\n<td>-5.8% (missed targets)<\/td>\n<\/tr>\n<tr>\n<td>May 2024<\/td>\n<td>Clinical Trial Results<\/td>\n<td>$25.40<\/td>\n<td>+18.9% (positive data)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Insight<\/strong>: GRAIL&#8217;s stock reacts strongly to clinical trial results and regulatory milestones. Positive data can trigger 15-20% jumps, while missed expectations typically cause 5-10% corrections.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6-Month Price Journey (February-August 2025)<\/h2>\n<p>GRAIL shares have been on a rollercoaster ride, showing why biotech investing requires strong nerves:<\/p>\n<ul>\n<li><strong>February<\/strong>: $63.99 (all-time high after breakthrough trial results)<\/li>\n<li><strong>March<\/strong>: $48.20 (profit-taking and volatility)<\/li>\n<li><strong>April<\/strong>: $41.50 (consolidation phase)<\/li>\n<li><strong>May<\/strong>: $38.50 (Q1 earnings strength)<\/li>\n<li><strong>June<\/strong>: $35.80 (summer slowdown)<\/li>\n<li><strong>July<\/strong>: $33.40 (market uncertainty)<\/li>\n<li><strong>August<\/strong>: $32.43 (current trading level)<\/li>\n<\/ul>\n<p>The stock has declined approximately <strong>49% from its February peak<\/strong> but still maintains impressive <strong>year-to-date gains of over 120%<\/strong>. This volatility is typical for development-stage biotech companies where clinical trial results can make or break the stock.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<ul>\n<li><strong>2025 Year-End<\/strong>: $38-42 (potential recovery after Q3 earnings and ESMO conference data) \u2192 <strong>BUY<\/strong><\/li>\n<li><strong>2026<\/strong>: $45-50 (FDA submission and expanded insurance coverage)<\/li>\n<li><strong>2028<\/strong>: $60-70 (mainstream adoption and international expansion)<\/li>\n<li><strong>2030<\/strong>: $85-100 (global market leadership and potential profitability)<\/li>\n<\/ul>\n<p><strong>Verdict<\/strong>: GRAIL represents a high-risk, high-reward opportunity ideal for investors with a <strong>3-5 year horizon<\/strong>. The current dip below $35 could be an attractive entry point for long-term believers.<\/p>\n<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2>\n<h3>Risks to Consider<\/h3>\n<ul>\n<li><strong>Regulatory uncertainty<\/strong>: FDA approval timeline remains unclear<\/li>\n<li><strong>Cash burn<\/strong>: $114 million Q2 loss despite revenue growth<\/li>\n<li><strong>Competition<\/strong>: Larger players entering multi-cancer detection space<\/li>\n<li><strong>False positives<\/strong>: Even 99.5% specificity means some incorrect results<\/li>\n<\/ul>\n<h3>Green Lights for 2025-2026<\/h3>\n<ul>\n<li><strong>Revenue growth<\/strong>: 29% increase in test sales shows market adoption<\/li>\n<li><strong>Clinical validation<\/strong>: PATHFINDER 2 results at ESMO October 2025<\/li>\n<li><strong>Partnership expansion<\/strong>: athenahealth EHR integration streamlines ordering<\/li>\n<li><strong>Market size<\/strong>: $50B+ potential in cancer screening market<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Start small<\/strong>: Allocate no more than 5% of your portfolio to high-volatility biotech stocks<\/li>\n<li><strong>Dollar-cost average<\/strong>: Buy in increments rather than one lump sum<\/li>\n<li><strong>Set stop-losses<\/strong>: Protect yourself from sudden 20%+ drops<\/li>\n<li><strong>Monitor catalysts<\/strong>: Watch for ESMO data in October and FDA updates<\/li>\n<\/ol>\n<p>Humorous take: &#8220;Trading GRAL is like dating someone with commitment issues\u2014exciting potential but prepare for emotional whiplash. Bring your risk tolerance and maybe some antacids.&#8221;<\/p>\n<h2>\u2705 How to Buy GRAIL, Inc. (GRAL) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a trading platform<\/td>\n<td>Ensure it offers NASDAQ stocks and reasonable fees<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Open and fund your account<\/td>\n<td>Start with an amount you&#8217;re comfortable potentially losing<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Search for &#8220;GRAL&#8221;<\/td>\n<td>Use the ticker symbol, not just &#8220;GRAIL&#8221;<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Select order type<\/td>\n<td>Limit order lets you set maximum purchase price<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Review and confirm<\/td>\n<td>Check commission fees and total cost before executing<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2>\n<p>Pocket Option makes stock investing accessible for everyone:<\/p>\n<ul>\n<li><strong>Minimum deposit just $5<\/strong>\u2014test strategies with real money without significant risk<\/li>\n<li><strong>1-minute verification<\/strong>\u2014upload any ID document and start trading immediately<\/li>\n<li><strong>100+ withdrawal methods<\/strong>\u2014from cryptocurrencies to e-wallets and bank cards<\/li>\n<li><strong>Fractional shares available<\/strong>\u2014buy pieces of expensive stocks like GRAL with small amounts<\/li>\n<\/ul>\n<p>The platform&#8217;s user-friendly interface and educational resources make it ideal for beginners dipping their toes into biotech investing.<\/p>\n<h2>\ud83c\udf0d GRAIL in 2025: Cancer Detection Pioneer<\/h2>\n<p>GRAIL dominates the emerging multi-cancer early detection market with their revolutionary Galleri test. The company&#8217;s technology can screen for over 50 cancer types through a simple blood draw, including hard-to-detect cancers like pancreatic and ovarian varieties.<\/p>\n<p><strong>Current market position<\/strong>: $1.27 billion market cap with 29% year-over-year test volume growth. The recent integration with athenahealth&#8217;s electronic health record platform makes ordering Galleri tests as easy as clicking a button for healthcare providers.<\/p>\n<p><strong>2025 fun fact<\/strong>: GRAIL&#8217;s CEO Bob Ragusa personally takes the Galleri test every six months\u2014not because he&#8217;s worried about cancer, but because he believes so strongly in the technology he&#8217;s helping build.<\/p>\n"},"faq":[{"question":"Is GRAIL profitable yet?","answer":"No, GRAIL is still in growth phase with a Q2 2025 net loss of $114 million. The company is investing heavily in research and market expansion."},{"question":"What's the biggest risk with GRAL stock?","answer":"Regulatory approval uncertainty. If the FDA doesn't approve the Galleri test or imposes strict limitations, the stock could decline significantly."},{"question":"How often does GRAIL report earnings?","answer":"Quarterly, like most public companies. The next report is expected around November 2025."},{"question":"Can I buy fractional shares of GRAL?","answer":"Yes, many platforms including Pocket Option offer fractional share trading, making expensive biotech stocks more accessible."},{"question":"What makes Galleri different from other cancer tests?","answer":"Galleri can detect over 50 cancer types from one blood draw, including cancers that currently have no standard screening methods."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Is GRAIL profitable yet?","answer":"No, GRAIL is still in growth phase with a Q2 2025 net loss of $114 million. The company is investing heavily in research and market expansion."},{"question":"What's the biggest risk with GRAL stock?","answer":"Regulatory approval uncertainty. If the FDA doesn't approve the Galleri test or imposes strict limitations, the stock could decline significantly."},{"question":"How often does GRAIL report earnings?","answer":"Quarterly, like most public companies. The next report is expected around November 2025."},{"question":"Can I buy fractional shares of GRAL?","answer":"Yes, many platforms including Pocket Option offer fractional share trading, making expensive biotech stocks more accessible."},{"question":"What makes Galleri different from other cancer tests?","answer":"Galleri can detect over 50 cancer types from one blood draw, including cancers that currently have no standard screening methods."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy GRAIL, Inc. (GRAL) shares - Investment in GRAIL, Inc. (GRAL) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy GRAIL, Inc. (GRAL) shares - Investment in GRAIL, Inc. (GRAL) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T11:25:50+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy GRAIL, Inc. (GRAL) shares &#8211; Investment in GRAIL, Inc. (GRAL) stock\",\"datePublished\":\"2025-08-20T11:25:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/\"},\"wordCount\":15,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/\",\"name\":\"How to buy GRAIL, Inc. (GRAL) shares - Investment in GRAIL, Inc. (GRAL) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"datePublished\":\"2025-08-20T11:25:50+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy GRAIL, Inc. (GRAL) shares &#8211; Investment in GRAIL, Inc. (GRAL) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy GRAIL, Inc. (GRAL) shares - Investment in GRAIL, Inc. (GRAL) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/","og_locale":"en_US","og_type":"article","og_title":"How to buy GRAIL, Inc. (GRAL) shares - Investment in GRAIL, Inc. (GRAL) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T11:25:50+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy GRAIL, Inc. (GRAL) shares &#8211; Investment in GRAIL, Inc. (GRAL) stock","datePublished":"2025-08-20T11:25:50+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/"},"wordCount":15,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/","name":"How to buy GRAIL, Inc. (GRAL) shares - Investment in GRAIL, Inc. (GRAL) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","datePublished":"2025-08-20T11:25:50+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-grail\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy GRAIL, Inc. (GRAL) shares &#8211; Investment in GRAIL, Inc. (GRAL) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":340397,"slug":"how-to-buy-grail","post_title":"Comment acheter des actions de GRAIL, Inc. (GRAL) - Investir dans les actions de GRAIL, Inc. (GRAL)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-grail\/"},"it_IT":{"locale":"it_IT","id":340399,"slug":"how-to-buy-grail","post_title":"Come acquistare azioni GRAIL, Inc. (GRAL) - Investire in azioni GRAIL, Inc. (GRAL)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-grail\/"},"pl_PL":{"locale":"pl_PL","id":340403,"slug":"how-to-buy-grail","post_title":"Jak kupi\u0107 akcje GRAIL, Inc. (GRAL) - Inwestycja w akcje GRAIL, Inc. (GRAL)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-grail\/"},"es_ES":{"locale":"es_ES","id":340402,"slug":"how-to-buy-grail","post_title":"C\u00f3mo comprar acciones de GRAIL, Inc. (GRAL) - Inversi\u00f3n en acciones de GRAIL, Inc. (GRAL)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-grail\/"},"th_TH":{"locale":"th_TH","id":340398,"slug":"how-to-buy-grail","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 GRAIL, Inc. (GRAL) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 GRAIL, Inc. (GRAL)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-grail\/"},"tr_TR":{"locale":"tr_TR","id":340400,"slug":"how-to-buy-grail","post_title":"GRAIL, Inc. (GRAL) Hisseleri Nas\u0131l Al\u0131n\u0131r - GRAIL, Inc. (GRAL) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-grail\/"},"vt_VT":{"locale":"vt_VT","id":340401,"slug":"how-to-buy-grail","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu GRAIL, Inc. (GRAL) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu GRAIL, Inc. (GRAL)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-grail\/"},"pt_AA":{"locale":"pt_AA","id":340404,"slug":"how-to-buy-grail","post_title":"Como comprar a\u00e7\u00f5es da GRAIL, Inc. (GRAL) - Investimento em a\u00e7\u00f5es da GRAIL, Inc. (GRAL)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-grail\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/340362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=340362"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/340362\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334027"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=340362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=340362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=340362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}